No Data
No Data
Cartesian Therapeutics Announces New Employment Inducement Grants
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $45
Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design
Express News | Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis
Insider Purchase: Director at $RNAC (RNAC) Buys 7,962 Shares